Showing results (111-120 of 125) with videos related to
Sort By:
Pageof 13
Advances in Biological Regulation|June 5, 2018
Roles of p53, NF-κB and the androgen receptor in controlling NGAL expression in prostate cancer cell linesWilliam H Chappell, Saverio Candido, Stephen L Abrams, et al.Expert Opinion on Emerging Drugs|September 1, 2009
Emerging Raf inhibitorsJames A McCubrey, Linda S Steelman, Steven L Abrams, et al.Expert Opinion on Emerging Drugs|February 16, 2010
Emerging MEK inhibitorsJames A McCubrey, Linda S Steelman, Steven L Abrams, et al.The Journal of Infection|November 17, 2021
Immunocompromised children and young people are at no increased risk of severe COVID-19H Chappell, R Patel, C Driessens, et al.Journal of Cellular Physiology|February 9, 2011
Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathwaysJames A McCubrey, Linda S Steelman, C Ruth Kempf, et al.Cell Cycle (Georgetown, Tex.)|November 20, 2012
Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberineWilliam H Chappell, Stephen L Abrams, Richard A Franklin, et al.Biochimica Et Biophysica Acta|November 28, 2006
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistanceJames A McCubrey, Linda S Steelman, William H Chappell, et al.Current Pharmaceutical Design|March 8, 2012
Targeting the cancer initiating cell: the ultimate target for cancer therapyJames A McCubrey, Linda S Steelman, Stephen L Abrams, et al.Oncogene|March 12, 2008
Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitorsL S Steelman, P M Navolanic, M L Sokolosky, et al.Oncotarget|September 26, 2012
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy responseJames A McCubrey, Linda S Steelman, William H Chappell, et al.Pageof 13